Key clinical point:
Major finding: The overall response rate was 53%.
Study details: A phase 1 trial involving 30 patients.
Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.
Source: Advani A et al. ASH 2017, Abstract 150.
Advani A et al. ASH 2017, Abstract 150.
This Week's Must Reads
ACP Guidance on Pharmacologic Treatment of T2D, Ann Intern Med; ePub 2018 Mar 6; Qaseem, et al
Opioid vs Nonopioid Meds for Pain-Related Function, JAMA; ePub 2018 Mar 6; Krebs, Gravely, et al
Obesity Progression and Incident Diabetes, Diabetes Care; ePub 2018 Mar 5; Stokes, et al
E-Cigarette Use and Progression to Smoking, Pediatrics; ePub 2018 Mar 5; Chaffee, et al
Intensive BP Treatment & Subsequent CVD Risk, J Am Coll Cardiol; ePub 2018 Mar 7; Phillips, et al
Must Reads in Oncology
Over half of refractory AML patients responded to combo, Advani A et al. ASH 2017, Abstract 150.
USPSTF: Screening for Ovarian Cancer, JAMA; 2018 Feb 13; USPSTF, Grossman, et al
Does Family History of Breast Cancer Increase Risk?, JAMA Intern Med; ePub 2018 Feb 12; Braithwaite, et al
Low-Dose CT Screening for Lung Cancer, CHEST; ePub 2018 Jan 25; Mazzone, et al
Risk of Breast Cancer with Hormonal Contraception, N Engl J Med; 2017 Dec 7; Mørch, Skovlund, et al